Last reviewed · How we verify
NCT03883880
Salivary Interactions With Chemosensations
NA trial testing Epigallocatechin gallate in Diet, Food Choice, Taste in 32 participants. Terminated before completion.
24 September 2019
Quick facts
| Lead sponsor | Purdue University |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 32 |
| Start date | 5 January 2019 |
| Primary completion | 24 September 2019 |
| Estimated completion | 1 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Epigallocatechin gallate
- Epigallocatechin gallate control
- Linoleic acid (LINOLEIC ACID) — full drug profile →
- Linoleic acid control
- Capsaicin solution
- Capsaicin control
Conditions studied
- Diet, Food Choice, Taste — all drugs for Diet, Food Choice, Taste →
Sponsor
Purdue University
Who can join
Adults 18 to 45, any sex, with Diet, Food Choice, Taste. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A counterbalanced, crossover design will be used to evaluate whether exposure to flavors vs. a control over time alters the perception of the flavor by changing an individual's salivary protein profile. Participants will complete 3 acute tasting protocols (baseline, after intervention 1, after intervention 2). The interventions will be with the flavor (epigallocatechin gallate, linolenic acid, capsaicin) or a control, in counterbalanced order, and will involve swishing and swallowing a solution of that sample 5 times per day for two weeks. Each of these flavors will be a separate sub-study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Repeated exposure to epigallocatechin gallate solution or water alters bitterness intensity and salivary protein profile.
Davis LA, Running CA. · · 2021 · cited 7× · PMID 34655570 · DOI 10.1016/j.physbeh.2021.113624
Verify or expand the search:
- PubMed search for NCT03883880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Purdue University trials
Trials by the same sponsor.
- NCT07287774 — Evaluating a Deep Neural Noise-Reduction Algorithm for Hearing Aids · NA · recruiting
- NCT07086833 — The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities · NA · recruiting
- NCT06638944 — Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease · Phase 2 · recruiting
- NCT07048392 — Retrieval-Based Word Learning in Developmental Language Disorder During Book Reading II · NA · recruiting
- NCT06258941 — Classroom Break, Cognition, and Fitness in Elementary School Children · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03883880 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Purdue University
- Last refreshed: 25 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03883880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing